NCT05570149Recruiting
EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
EptinezuMaB in ReAl-world evidenCE: a 12-Months, Multicenter, Real-Life, Cohort Study in High-Frequency Episodic and Chronic Migraine (the EMBRACE Study)
Source: ClinicalTrials.gov · Last updated 1 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 4 Oct 2022
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- IRCCS San Raffaele Roma
- Diseases
- Migraine
- NCT number
- NCT05570149
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jan 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with other mAbs;
Other illness
- Vascular disease or Raynaud.
Other
- Other headaches different than migraine;
- Known intolerance to eptinezumab or eccipients;
Who the study is looking for
- Age between 18 and 75 years;
- Males and females;
- Willingness to sign the informed consent;
- High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
- Chronic migraine, according to the ICHD-III criteria;
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS San Raffaele Roma Coordinator of this site? Confirm its status | Roma | Italy | Recruiting |
Related publications
- Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.Neurol Ther · 2026 · PMID 42262724
This page is information, not medical advice. Discuss any trial with your doctor.